Clinical and economic impact of first-line or drug-naïve catheter ablation and delayed second-line catheter ablation for atrial fibrillation using a patient-level simulation model
Increased first-line or drug-naïve catheter ablation, and shorter AAT, could increase the proportion of patients with controlled AF and reduce AEs, offsetting the small investment required in total AF costs over 10 years in Italy and France.
Authors
- Daniel Grima (ORCID: https://orcid.org/0000-0003-2605-128X)
- Roberto De Ponti (ORCID: https://orcid.org/0000-0003-3278-1721)
- Graça Costa (ORCID: https://orcid.org/0009-0007-9161-9173)
- Lucas Cohen (ORCID: https://orcid.org/0000-0003-1666-7398)
- Marike Hempel (ORCID: https://orcid.org/0009-0009-3810-8299)
- Elena Arbelo (ORCID: https://orcid.org/0000-0003-0424-6393)
- Laura Pastor (ORCID: https://orcid.org/0000-0002-5657-8464)
Institutions
- University of Insubria (IT)
- Johnson & Johnson (Switzerland) (CH)
- Centro de Investigación en Red en Enfermedades Cardiovasculares (ES)
- Centro de Investigación Biomédica en Red (ES)
- ERN GUARD-Heart (NL)
- EVERSANA (Canada) (CA)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Johnson & Johnson (Brazil) (BR)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1080/13696998.2024.2399438
- Citations
- 1
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.40